Home Jazz Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owns $2.21 million worth of shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owns $2.21 million worth of shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

0

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 1.5% during the 1st quarter, according to its latest filing with the Securities and Exchange Commission (SEC). The fund held 14,204 shares of the specialty pharmaceutical company after selling 213 shares during the period. The holdings of Mitsubishi UFJ Kokusai Asset Management Co. Ltd. in Jazz Pharmaceuticals were worth $2,211,000 at the end of the last quarter.

Other institutional investors have also recently changed their stake in the company. Private Capital Group LLC increased its equity stake in Jazz Pharmaceuticals by 1,975.0% during the 1st quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company worth $26,000 after purchasing an additional 158 shares during the period. Lloyd Advisory Services LLC. bought a new stake in shares of Jazz Pharmaceuticals during Q1 worth approximately $29,000. Quent Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during Q4 for a value of approximately $31,000. CWM LLC purchased a new stake in shares of Jazz Pharmaceuticals during Q4 for a value of approximately $43,000. Finally, CM Bidwell & Associates Ltd. bought a new stake in shares of Jazz Pharmaceuticals during Q1 for a value of approximately $45,000. 93.23% of the shares are currently held by institutional investors and hedge funds.

Analysts set new price targets

JAZZ has been the subject of several research analyst reports. Cowen raised his price target on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a Thursday, May 5 report. StockNews.com moved shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report released Wednesday. SVB Leerink raised its price target on Jazz Pharmaceuticals shares from $200.00 to $210.00 and gave the company an “outperform” rating in a Thursday, Aug. 4, report. HC Wainwright cut its price target on shares of Jazz Pharmaceuticals from $210.00 to $204.00 in a Friday, August 5 report. Finally, Piper Sandler cut her price target on Jazz Pharmaceuticals shares from $197.00 to $193.00 in a Thursday, May 5 report. Two equity research analysts gave the stock a hold rating, nine gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $203.69.

Insider Trading at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 6,362 shares of the company in a trade that took place on Wednesday, June 1. The shares were sold at an average price of $146.87, for a total transaction of $934,386.94. Following completion of the transaction, the CEO now directly owns 351,987 shares of the company, valued at approximately $51,696,330.69. The transaction was disclosed in a filing with the SEC, which is available on the SEC’s website. In related news, CEO Bruce C. Cozadd sold 8,775 shares of the company in a trade that took place on Tuesday, July 5. The shares were sold at an average price of $157.28, for a total transaction of $1,380,132.00. Following completion of the transaction, the CEO now directly owns 351,912 shares of the company, valued at approximately $55,348,719.36. The transaction was disclosed in a filing with the SEC, which is available on the SEC’s website. Additionally, CEO Bruce C. Cozadd sold 6,362 shares of the company in a trade that took place on Wednesday, June 1. The stock was sold at an average price of $146.87, for a total transaction of $934,386.94. As a result of the transaction, the CEO now owns 351,987 shares of the company, valued at $51,696,330.69. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 48,093 shares of the company valued at $7,436,900. Insiders of the company hold 4.40% of the shares of the company.

Jazz Pharmaceuticals stock performance

Shares of Jazz Pharmaceuticals opened at $157.08 on Friday. The company has a 50-day moving average of $153.67 and a 200-day moving average of $152.44. Jazz Pharmaceuticals plc has a 1-year low of $117.64 and a 1-year high of $169.98. The company has a current ratio of 3.67, a quick ratio of 2.45 and a debt ratio of 1.87. The company has a market capitalization of $9.81 billion, a PE ratio of -184.80, a growth price-earnings ratio of 1.30 and a beta of 0.69.

About Jazz Pharmaceuticals

(Get an assessment)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and markets pharmaceutical products for a variety of unmet medical needs in the United States, Europe and globally. The Company has a portfolio of products and product candidates focused on areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Want to see which other hedge funds hold JAZZ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating).

Institutional ownership by quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)



Get news and reviews for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.